Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Flingai, Seleeke ^a   Plummer, Emily M ^b   Patel, Ami ^a   Shresta, Sujan ^b   Mendoza, Janess M ^c   Broderick, Kate E ^c   Sardesai, Niranjan Y ^c   Muthumani, Kar ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c Inovio Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NUCLEIC ACID; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL; C57BL MOUSE; CELL LINE; CHLOROCEBUS AETHIOPS; CROSS REACTION; DENGUE; DENGUE VIRUS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; K-562 CELL LINE; MOUSE; PROCEDURES; SERODIAGNOSIS; VERO CELL LINE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; IMMUNOTHERAPY; K562 CELLS; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; NUCLEIC ACIDS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 84938244572     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12616     Document Type: Article

References (34)

1. Bhatt, S. et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
2. Gubler, D. J. The economic burden of dengue. Am. J. Trop. Med. Hyg. 86, 743-744 (2012).
3. Rothman, A. L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113, 946-951 (2004).
4. Halstead, S. B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140, 527-533 (1979).
5. Peiris, J. S. & Porterfield, J. S. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282, 509-511 (1979).
6. Peiris, J. S., Gordon, S., Unkeless, J. C. & Porterfield, J. S. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 289, 189-191 (1981).
7. Capeding, M. R. et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358-1365 (2014).
8. Villar, L. et al. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N. Engl. J. Med. 372, 113-123 (2014).
9. Sabchareon, A. et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380, 1559-1567 (2012).
10. Leitmeyer, K. C. et al. Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73, 4738-4747 (1999).
11. Kaufman, B. M., Summers, P. L., Dubois, D. R. & Eckels, K. H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36, 427-434 (1987).
12. Lai, C. J. et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J. Virol. 81, 12766-12774 (2007).
13. Kyle, J. L., Balsitis, S. J., Zhang, L., Beatty, P. R. & Harris, E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380, 296-303 (2008).
14. Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271-283 (2010).
15. Sukupolvi-Petty, S. et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84, 9227-9239 (2010).
16. Shrestha, B. et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 6, e1000823 (2010).
17. Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901-906 (2009).
18. Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81-84 (2012).
19. Balazs, A. B. et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20, 296-300 (2014).
20. Limberis, M. P. et al. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci. Transl. Med. 5, 187ra172 (2013).
21. Limberis, M. P. et al. Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9. Clin. Vaccine Immunol. 20, 1836-1837 (2013).
22. Balazs, A. B., Bloom, J. D., Hong, C. M., Rao, D. S. & Baltimore, D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat. Biotechnol. 31, 647-652 (2013).
23. MacGregor, R. R., Boyer, J. D., Ciccarelli, R. B., Ginsberg, R. S. & Weiner, D. B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J. Infect. Dis. 181, 406 (2000).
24. Klinman, D. M. et al. DNA vaccines: capacity to induce auto-immunity and tolerance. Dev. Biol. (Basel) 104, 45-51 (2000).
25. Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776-788 (2008).
26. Muthumani, K. et al. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum. Vaccin. Immunother. 9, 2253-2262 (2013).
27. Tjelle, T. E. et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol. Ther. 9, 328-336 (2004).
28. Sardesai, N. Y. & Weiner, D. B. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23, 421-429 (2011).
29. Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007).
30. Zellweger, R. M., Prestwood, T. R. & Shresta, S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7, 128-139 (2010).
31. Shresta, S., Sharar, K. L., Prigozhin, D. M., Beatty, P. R. & Harris, E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80, 10208-10217 (2006).
32. Moore, A. C., Kong, W. P., Chakrabarti, B. K. & Nabel, G. J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J. Virol. 76, 243-250 (2002).
33. Villarreal, D. O. et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 74, 1789-1800 (2014).
34. Medina, F. et al. Dengue virus: isolation, propagation, quantification, and storage. Curr. Protoc. Microbiol. 27, 15D. 2. 1-15D. 2. 24 (2012).